Received in the Senate and Read twice and referred to the Committee on Veterans' Affairs.
Requires the Secretary of Veterans Affairs to contract with the National Academies to study cancer prevalence and mortality among active-duty fixed-wing aircrew, identify related occupational exposures, review literature on specific cancers, and estimate prevalence/mortality using VA, DoD, and national data sources. The Academies must report results to the VA and Veterans' Affairs committees.
Progressives emphasize using study to justify presumptive benefits.
Relative to its intended legislative type, this bill is a well-scoped and specific directive to commission a National Academies study, with clear tasks and an accountable recipient for the findings; however, it omits several practical implementation elements commonly expected for such studies, most notably funding authorization, an explicit study timeline, and detailed data-access and privacy provisions.
Requires the Secretary of Veterans Affairs to contract with the National Academies to study cancer prevalence and mortality among active-duty fixed-wing aircrew, identify related occupational exposures, review literature on specific cancers, and estimate prevalence/mortality using VA, DoD, and national data sources.
The Academies must report results to the VA and Veterans' Affairs committees.
The bill also amends 38 U.S.C. 5503(d)(7) to extend a statutory date from November 30, 2031 to December 31, 2031.
Narrow, technical, low-cost study for veterans typically attracts bipartisan support; procedural timing and resourcing remain the main barriers.
Relative to its intended legislative type, this bill is a well-scoped and specific directive to commission a National Academies study, with clear tasks and an accountable recipient for the findings; however, it omits several practical implementation elements commonly expected for such studies, most notably funding authorization, an explicit study timeline, and detailed data-access and privacy provisions.
Progressives emphasize using study to justify presumptive benefits.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize using study to justify presumptive benefits.
Generally supportive: views the study as needed to document service-related cancer risks and to inform veterans' benefits.
Would press for broad scope, public transparency, and follow-up policy to address findings.
Cautiously favorable: sees an independent study as a sensible, evidence-based step to assess veteran cancer risks.
Wants clear timelines, budget clarity, and avoidance of redundant research.
Qualified support with caution: accepts studying veteran health concerns but worries study could be a pretext for costly presumptive benefits and expanded liability.
Emphasizes tight scope, fiscal restraint, and methodological rigor.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, technical, low-cost study for veterans typically attracts bipartisan support; procedural timing and resourcing remain the main barriers.
The House fast-tracked this bill — skipping normal debate — and it passed with a two-thirds majority. It now moves to the Senate.
Suspending the rules allows the House to bypass normal debate procedures and pass a bill immediately with a two-thirds vote.
Progressives emphasize using study to justify presumptive benefits.
Narrow, technical, low-cost study for veterans typically attracts bipartisan support; procedural timing and resourcing remain the main barr…
Relative to its intended legislative type, this bill is a well-scoped and specific directive to commission a National Academies study, with clear tasks and an accountable recipient for the findings; however, it omits se…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.